CABALETTA BIO, INC. Operating Lease Cost
CABALETTA BIO, INC. (CABA) reported Operating Lease Cost of $4.21 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-23
- CABALETTA BIO, INC. operating lease, cost for the quarter ending 2023-12-31 was $780.00K.
- CABALETTA BIO, INC. operating lease, cost for the quarter ending 2023-09-30 was $584.00K.
- CABALETTA BIO, INC. operating lease, cost for the quarter ending 2023-06-30 was $557.00K.
- CABALETTA BIO, INC. operating lease, cost for the quarter ending 2023-03-31 was $556.00K.
- CABALETTA BIO, INC. operating lease, cost for fiscal 2025 was $4.21M, a 29.69% increase from fiscal 2024.
- CABALETTA BIO, INC. operating lease, cost for fiscal 2024 was $3.25M, a 31.09% increase from fiscal 2023.
- CABALETTA BIO, INC. operating lease, cost for fiscal 2023 was $2.48M, a 18.57% decline from fiscal 2022.
- CABALETTA BIO, INC. operating lease, cost for fiscal 2022 was $3.04M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.21M 10-K · filed 2026-03-23 | |||
| 2024-12-31 | $3.25M 10-K · filed 2026-03-23 | |||
| 2023-12-31 | $780.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.36M derived: sum of 2 quarters · filed 2025-03-31 | $1.92M derived: sum of 3 quarters · filed 2025-03-31 | $2.48M 10-K · filed 2025-03-31 |
| 2023-09-30 | $584.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.14M derived: sum of 2 quarters · filed 2023-11-09 | $1.70M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $557.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.11M 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $556.00K 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $3.04M 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |